Clinical Trials Logo

Autism Spectrum Disorder clinical trials

View clinical trials related to Autism Spectrum Disorder.

Filter by:

NCT ID: NCT03805828 Recruiting - Clinical trials for Autism Spectrum Disorder

Effectiveness of Educational Program on Parenting Stress and Coping Mechanism Among Parents of Children With Autism Spectrum Disorder in Amman, Jordan

Start date: March 1, 2019
Phase: N/A
Study type: Interventional

Health and well being of children are inextricably linked to the physical, emotional and psychological of their parents. Autism Spectrum Disorder is one of the neurological developmental disorders characterized by moderate to severe impairments in social interactions, language, and cognitive development, as well as included repetitive behaviors, restricted interests, and emotional distress. Coping with a stressful situation is classified as one of the most challenges in one's life. The overall aim of this study is to examine the effectiveness of the educational program on parenting stress and coping mechanism among parents of children with ASD in Amman, Jordan at baseline, post-test and at two months follow-up assessment. Two hundred parents of children with Autism spectrum disorder will be assigned to the intervention group (n = 100) and the control group (n = 100). Measures of parent stress and coping mechanism using the parent stress index(PSI) and Brief COPE will administer at pre-, post-treatment, and 2-months follow-up.

NCT ID: NCT03778827 Recruiting - Clinical trials for Autism Spectrum Disorder

A Center Based Study of Pivotal Response Treatment for Preschoolers With Autism

PRT-C
Start date: May 13, 2019
Phase: N/A
Study type: Interventional

The purpose of this study is to examine the effectiveness of pivotal response training (PRT) in an intensive center-based environment to treat social communication deficits in children with autism spectrum disorder (ASD).

NCT ID: NCT03769571 Recruiting - Clinical trials for Autism Spectrum Disorder

Generalized Training Program for Caregivers on the ESDM: PEGASE

PEGASE
Start date: November 8, 2018
Phase: N/A
Study type: Interventional

The main objective of the study is to evaluate the effectiveness of a parent's training program (name PEGASE) of young children (aged 2 to 4 years) with Autism Spectrum Disorders. This study is follow up by the Autism Resource Center PACA (CRA PACA), which is located in Marseille's university Department of Child Psychiatry. This center is a regional expert center in diagnostic and research missions in the field of Autism. The center is promoting new advances in the field of Autism Spectrum Disorders (ASD) The center receives requests for diagnostic assessment from all the region. Autism is to date a major public health problem, current prevalence rates are 1 child / 88 in the United States. This prevalence continues to increase. Autism is a severe neurodevelopment disorder with significant functional impact. An essential axis in the field of health is to develop new treatment strategy including low costs and family impact particularly in quality of life. In France, consensus guidelines (HAS 2012) on the diagnosis assessment for Autism Spectrum Disorders (ASD) people and interventions were edited. Support for grade recommendations have been issued. In this research, the investigators focus on a global, early and coordinated management method: the Early Start Denver Model. This intervention obtained a grade B to the recommendations of the HAS in 2012. Early Start Denver Model (ESDM) is scientifically proven by a lots of studies. Two management modalities are discuss in the ESDM model: the classical ESDM and the ESDM P (parents ESDM). Even if in both ways of care, the parent is put in a central position around the care of the child. In P ESDM, the parent is trained in the techniques of ESDM itself. This parental coaching program at ESDM (P-ESDM) was developed by Rogers et al at Sacramento Davis University. P ESDM is not yet developed in France and has not been the subject of any French-language publication to date. This program is dedicated to young parents of children with autism spectrum disorders aged between 2 and 4 years old. This is a 7-month program (with a duration of inclusion of 3 year). The program is based on ESDM techniques, it meets both the need to include parents in care and the idea of reducing the cost of these care (need fewer hours of care by professionals). This program is offered to all parents of autism spectrum disorders children between the ages of 2 and 4 who go to CRA PACA for an expert diagnostic evaluation. The aim of this study is to objectify the effectiveness of this parental intervention in a French population.

NCT ID: NCT03757585 Recruiting - Clinical trials for Autism Spectrum Disorder

Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)

Start date: May 20, 2019
Phase: Phase 4
Study type: Interventional

This study consists of a 6-week, open-label, randomized clinical trial study to compare efficacy and tolerability of the natural treatments omega-3 fatty acids, inositol, and N-acetylcysteine (NAC) in the treatment of mood dysregulation in children and adolescents with non-verbal learning disability (NVLD) or Autism Spectrum Disorder (ASD). Subjects will include youth ages 5-17 years with a non-verbal learning disability (NVLD) or autism spectrum disorder (ASD) and current symptoms of emotional dysregulation.

NCT ID: NCT03718936 Recruiting - Clinical trials for Autism Spectrum Disorder

ADNP Syndrome: The Seaver Autism Center for Research and Treatment is Characterizing ADNP-related Neurodevelopmental Disorders Using Genetic, Medical, and Neuropsychological Measures.

Start date: November 14, 2017
Phase:
Study type: Observational

ADNP, also known as Activity Dependent Neuroprotective Protein, is a rare neurodevelopmental disorder caused by mutations encompassing the ADNP gene on chromosome 20. Clinically, ADNP syndrome is characterized by intellectual disability and global developmental delay. This study seeks to characterize ADNP-related neurodevelopmental disorders using a number of genetic, medical and neuropsychological measures.

NCT ID: NCT03718923 Recruiting - Clinical trials for Autism Spectrum Disorder

FOXP1 Syndrome: The Seaver Autism Center for Research and Treatment is Characterizing FOXP1-related Neurodevelopmental Disorders Using Genetic, Medical, and Neuropsychological Measures.

Start date: March 28, 2016
Phase:
Study type: Observational

FOXP1, also known as Forkhead-box Protein P1, is a transcription factor protein belonging to the FOX gene family. Disruptions in the FOXP1 gene cause a phenotype characterized by global developmental delay, speech deficits, mild dysmorphic features, and traits of autism spectrum disorder. This study seeks to characterize FOXP1-related neurodevelopmental disorders using a number of genetic, medical and neuropsychological measures.

NCT ID: NCT03718910 Recruiting - Clinical trials for Autism Spectrum Disorder

DDX3X Syndrome -The Seaver Autism Center for Research and Treatment is Characterizing DDX3X-related Neurodevelopmental Disorders Using Genetic, Medical, and Neuropsychological Measures.

Start date: May 22, 2018
Phase:
Study type: Observational

DDX3X syndrome is a genetic cause of intellectual disability and other neurologic features including, in some cases, autism. Variants in the DDX3X gene are thought to account for 1-3% of unexplained intellectual disability in females, making it one of the more common causes of intellectual disability.This study seeks to characterize DDX3X-related neurodevelopmental disorders using a number of genetic, medical and neuropsychological measures.

NCT ID: NCT03708614 Recruiting - Clinical trials for Autism Spectrum Disorder

A Study Looking at How Well Children With Autism Spectrum Disorder on Medications Like Having More Protein

Start date: December 7, 2018
Phase: N/A
Study type: Interventional

Antipsychotic medications are commonly prescribed in children and adults with ASD (Curtin, Jojic & Bandini, 2014). But weight gain has been known to be one of the less desirable effects of these medications, increasing one's risk for overweight and obesity. Based on experience in Holland Bloorview's Nutrition Clinic, working with a dietitian to follow specific dietary advice, such as having more protein while keeping the amount of calories the same, may be a possible and useful way to limit weight gain. This study's objective is to evaluate the feasibility (study designs, methods, processes) and acceptability (client/family satisfaction, perceived effectiveness) of a controlled energy diet with elevated protein intake in children and youth with ASD who are currently taking prescribed atypical antipsychotic medication.

NCT ID: NCT03700190 Recruiting - Clinical trials for Autism Spectrum Disorder

The Predictors for Activity and Participation in Children With ASD: A Follow-up Study

Start date: August 1, 2017
Phase:
Study type: Observational

Developmental function and Participation in life and school activities in patients with autism spectrum disorder: A follow-up study

NCT ID: NCT03678129 Recruiting - Clinical trials for Autism Spectrum Disorder

GABA Pathways in Autism Spectrum Disorder (ASD)

Start date: December 7, 2018
Phase: N/A
Study type: Interventional

This study investigates the brain response to a single acute dose of a GABAa receptor acting drug (Benzodiazepine or positive allosteric modulator) compared to a single dose of placebo in adults with and without autism spectrum disorder.